Travere Therapeutics (TVTX) Cash from Operations (2011 - 2026)
Travere Therapeutics (TVTX) posted Cash from Operations of 40366000.0 for Q1 2026, down 166.52% on a QoQ basis from 60678000.0 in Q4 2025, and up 4.33% year-over-year from 38689814.27 in Q1 2025.
Travere Therapeutics (TVTX) Cash from Operations (2011 - 2026) Analysis & Trends
Travere Therapeutics' Cash from Operations history runs 16 years deep, the most recent figure standing at 40366000.0 for Q1 2026.
- Quarterly Cash from Operations rose 4.33% year-over-year to 40366000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 39612000.0 (up 124.64% YoY) and the FY2025 annual result came in at 37784000.0, up 115.91% from the prior year.
- Cash from Operations was 40366000.0 for Q1 2026 at Travere Therapeutics, down from 60678000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 60678000.0 in Q4 2025 and bottomed at 118902000.0 in Q1 2024.
- A 5-year average of 44217941.18 and a median of 42145000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations tumbled 666.59% — and 2025, when it surged 268.17%.
- Travere Therapeutics' Cash from Operations stood at 54640000.0 in 2022, then tumbled by 111.95% to 115809000.0 in 2023, then soared by 68.84% to 36082000.0 in 2024, then jumped by 268.17% to 60678000.0 in 2025, then tumbled by 166.52% to 40366000.0 in 2026.
- Business Quant data shows TVTX's Cash from Operations at 40366000.0 in Q1 2026, 60678000.0 in Q4 2025, and 14317000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | -40.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.37 Mn |
| Mar 31, 2026 | -40.37 Mn |
| Dec 31, 2025 | 60.68 Mn |
| Dec 31, 2025 | 60.68 Mn |
| Sep 30, 2025 | 14.32 Mn |
| Sep 30, 2025 | 14.32 Mn |
| Jun 30, 2025 | 4.98 Mn |
| Jun 30, 2025 | 4.98 Mn |
| Mar 31, 2025 | -42.19 Mn |
| Mar 31, 2025 | -42.19 Mn |
| Dec 31, 2024 | -36.08 Mn |
| Dec 31, 2024 | -36.08 Mn |
| Sep 30, 2024 | -42.15 Mn |
| Sep 30, 2024 | -42.15 Mn |
| Jun 30, 2024 | -40.35 Mn |
| Jun 30, 2024 | -40.35 Mn |
| Mar 31, 2024 | -118.90 Mn |
| Mar 31, 2024 | -118.90 Mn |
| Dec 31, 2023 | -115.81 Mn |
| Dec 31, 2023 | -115.81 Mn |